

CLINICAL TRIAL RESULTS
Choose POWERFUL efficacy: choose KESIMPTA® (ofatumumab)
The POWER of superior reduction in relapses vs Aubagio
Review ASCLEPIOS I and II Study DesignSuperior relapse reductions of up to nearly 60% vs Aubagio
Primary end point: relative reduction in annualized relapses
vs Aubagio® (teriflunomide)1,2
Primary end point: relative
reduction in annualized relapses
vs Aubagio® (teriflunomide)1,2

0.1 RELAPSE PER YEAR IS THE EQUIVALENT OF
1 RELAPSE EVERY 10 PATIENT-YEARS*
*Based on ARR primary end point results.
Your patients expect fewer relapses. Start KESIMPTA in recently relapsed RMS patients.
Early and continued relapse reduction over the study period3,4*
Post hoc analysis of pooled data from ASCLEPIOS I and II
Cumulative ARR by time interval
Cumulative ARR by time interval

N'=total number of patients included in the analysis.
No conclusions can be drawn.
Post hoc study design: ARR by time intervals was analyzed from the pooled pivotal trials. The ARR (95% CI) was estimated separately for each time interval by fitting a negative binomial regression model adjusted for treatment as factor.
*Reduction in ARR seen in the first 3 months and time intervals over 2 years.
Your RMS patients expect a treatment that reduces relapses early on. Offer KESIMPTA to recently diagnosed patients.
The POWER to help reduce MRI lesion activity
Near complete suppression of Gd+ T1 and T2 lesion activity
Profound reduction in active inflammatory Gd+ T1 lesions vs Aubagio
Mean number of Gd+ T1 lesions per MRI scan1,2
Mean number of Gd+ T1 lesions
per MRI scan1,2

Superior reductions in T2 lesions
vs Aubagio
Mean number of new or enlarging T2 lesions per year1,2
Mean number of new or
enlarging T2 lesions per year1,2

*Negative binomial regression model.
MRI lesion activity is a hallmark of worsening RMS. Initiate KESIMPTA in RMS patients at the first sign of MRI lesion activity.
The POWER to fight the risk of disability progression
Significantly reduced confirmed disability progression vs Aubagio
In a prespecified meta-analysis of pooled data from ASCLEPIOS I and II, KESIMPTA reduced the risk of CDP vs Aubagio.1,2

34%
REDUCED RISK AT 3 MONTHS
(10.9% vs 15.0% with Aubagio, P=0.003)
32%
REDUCED RISK AT 6 MONTHS6
REDUCED RISK AT 6 MONTHS6
(8.1% vs 12.0% with Aubagio, P=0.01)
Proportion of patients with 3-month CDP refers to Kaplan-Meier estimates at month 24.
Disability progression was defined as an increase in EDSS of at least 1.5, 1, or 0.65 points in patients with a baseline EDSS of 0, 1 to 5, or 5.5 or greater, respectively.
Delay tomorrow's progression:
take the first step today with KESIMPTA.

There may be a different treatment that's right for me.
Kristin: mom, real estate agent, KESIMPTA patient*
For adults only.


*Actual KESIMPTA patient who was compensated for their time. Individual results may vary.
Dig deeper into the data on KESIMPTA efficacy for patients with RMS.
Review the pivotal and post hoc analysisStart patients on KESIMPTA today
DOWNLOAD START FORMSubmit a Start Form by fax or online at CoverMyMeds®
VISIT COVERMYMEDS®ARR=annualized relapse rate; CDP=confirmed disability progression; CI=confidence interval; EDSS=Expanded Disability Status Scale; Gd+=gadolinium-enhancing; MOA=mechanism of action; MRI=magnetic resonance imaging; RMS=relapsing multiple sclerosis.
References: 1. Kesimpta [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp. 2. Hauser SL, Bar-Or A, Cohen JA, et al; for the ASCLEPIOS I and ASCLEPIOS II trial groups. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med. 2020;383(6):546-557. 3. Hauser SL, Bar-Or A, Cohen JA, et al. Ofatumumab vs teriflunomide in relapsing multiple sclerosis: analysis of no evidence of disease activity (NEDA-3) from ASCLEPIOS I and II trials. LB62. Poster presented at: 6th Congress of the European Academy of Neurology; May 23-26, 2020; Virtual. 4. Data on file. OMB157G (ofatumumab). Summary of clinical efficacy in relapsing multiple sclerosis. Novartis Pharmaceuticals Corp; East Hanover, NJ. December 2019. 5. Data on file. OMB157 (ofatumumab). ASCLEPIOS I Final clinical study report. Novartis Pharmaceuticals Corp; East Hanover, NJ. November 2022. 6. Data on file. OMB157 (ofatumumab). Final clinical study report. Meta-analysis of ASCLEPIOS I/II. Novartis Pharmaceuticals Corp; East Hanover, NJ. November 2022.